Surrogate markers of response to cancer immunotherapy
- 1 March 2001
- journal article
- Published by Taylor & Francis in Expert Opinion on Biological Therapy
- Vol. 1 (2) , 153-158
- https://doi.org/10.1517/14712598.1.2.153
Abstract
(2001). Surrogate markers of response to cancer immunotherapy. Expert Opinion on Biological Therapy: Vol. 1, No. 2, pp. 153-158.Keywords
This publication has 32 references indexed in Scilit:
- Rapid generation of broad T-cell immunity in humans after a single injection of mature dendritic cellsJournal of Clinical Investigation, 1999
- Immunotherapy of Metastatic Malignant Melanoma by a Vaccine Consisting of Autologous Interleukin 2-Transfected Cancer Cells: Outcome of a Phase I StudyHuman Gene Therapy, 1999
- Evaluation of Immunological Responses in Patients with Ovarian Cancer Treated with the Anti-idiotype Vaccine ACA125 by Determination of Intracellular Cytokines—A Preliminary ReportHybridoma, 1999
- Vaccination with IL-12 gene-modified autologous melanoma cells: preclinical results and a first clinical phase I studyGene Therapy, 1998
- Evaluation of the interferon-γ ELISPOT-assay for quantification of peptide specific T lymphocytes from peripheral bloodJournal of Immunological Methods, 1997
- Phenotypic Analysis of Antigen-Specific T LymphocytesScience, 1996
- Real time quantitative PCR.Genome Research, 1996
- Quantification of antigen specific CD8+ T cells using an ELISPOT assayJournal of Immunological Methods, 1995
- Longitudinal analysis of T cell receptor (TCR) gene usage by human immunodeficiency virus 1 envelope-specific cytotoxic T lymphocyte clones reveals a limited TCR repertoire.The Journal of Experimental Medicine, 1994
- T cell receptor (TCR) structure of autologous melanoma-reactive cytotoxic T lymphocyte (CTL) clones: tumor-infiltrating lymphocytes overexpress in vivo the TCR beta chain sequence used by an HLA-A2-restricted and melanocyte-lineage-specific CTL clone.The Journal of Experimental Medicine, 1993